INVESTORS & MEDIA

Press Releases


Press Releases

December 9, 2019
- PBCAR0191 continues to be associated with no serious adverse events or dose limiting toxicities observed to date, and no cases of graft-versus-host disease- -Seven of nine treated patients (78%) had objective evidence of tumor shrinkage at any timepoint- -R/R non-Hodgkin lymphoma (NHL) cohort...
November 6, 2019
-Preliminary data from ongoing Phase 1/2a trial of PBCAR0191 for the treatment of relapsed/refractory non-Hodgkin lymphoma or relapsed/refractory B-cell precursor acute lymphoblastic leukemia- -Abstract summarizes early results from first three patients with advanced NHL treated with PBCAR0191 at...
September 26, 2019
Company to Participate in the Alliance for Regenerative Medicine Cell & Gene Meeting on the Mesa, Chardan Genetic Medicines Conference and Jefferies Gene Therapy Summit DURHAM, N.C., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a genome editing company dedicated to...
September 23, 2019
DURHAM, N.C., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a genome editing company dedicated to improving life through the application of its pioneering, proprietary ARCUS ® platform, announced today that David Thomson, PhD, has been appointed to the position of...
September 4, 2019
DURHAM, N.C., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life through the application of its pioneering, proprietary ARCUS® platform, is participating in several upcoming presentations on chimeric...
Displaying 1 - 10 of 27